Print this page    •   Back to Web version of article

Update on Sculptra (New-Fill) Hearing

March 26, 2004

On March 25 an FDA advisory panel unanimously recommended that the FDA approve Sculptra (New-Fill) for facial wasting caused by HIV treatment or HIV. They also want restrictions so that it will not be used widely for less urgent purposes like filling wrinkles, unless the company (Dermik Laboratories) comes back with data to support that use. The committee was not happy with the limited amount of data available, but was moved by HIV patients' testimony about their need for the treatment.

Back to the AIDS Treatment News March 26, 2004 contents page.

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.